Mirificin
Based on 1 Customer Validation
Mirificin (Puerarin apioside) is a blood-brain barrier-permeable tyrosinase inhibitor, with an IC50 value of 12.66 μM against mushroom tyrosinase. Mirificin reduces the expression of ALOX12 in cardiomyocytes and alleviates hypoxia/reoxygenation-induced apoptosis. The neuroprotective effect of Mirificin depends on the activation of VEGFR2 and HSP1A1, which reduces cerebral infarct size and improves neurological function. Mirificin can be used in the research of hyperpigmentation, acute myocardial infarction and ischemic stroke.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.66%
- No. CAS: 103654-50-8
- Fòrmula: C26H28O13
- Peso molecular:548.49
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-N0192
Arbutin
-
HY-N0616
Trifolirhizin
-
HY-107369
4-Butylresorcinol
-
HY-N0192R
Arbutin (Standard)
-
HY-W003607
3-O-Ethyl-L-ascorbic acid
-
HY-N1775
3',4'-Dihydroxyacetophenone
-
HY-N3266
Methyl rosmarinate
-
HY-N3518
Mulberroside F
-
HY-101445A
(R)-Trolox
-
HY-N10503
Norartocarpetin
-
HY-113068
(rel)-β-Tocopherol
-
HY-N2204
Swertiajaponin
Ver todos los productos específicos de isoformas VEGFR
More
Actividad biológica
|
12-LOX |
VEGFR-2 |
HSP1A1 |
Mirificin (20.0 μM) shows no toxicity to H9c2 rat cardiomyocytes, even at the highest concentration tested[2].
Mirificin (5-50 μM; 24 h) dose-dependently increases the viability and reduces the cytotoxicity of differentiated PC12 cells with oxygen-glucose deprivation/reperfusion (OGD/R) injury[3].
Mirificin (0.1-10.0 μM) significantly reduces the mRNA expression level of Alox12 in H9c2 rat cardiomyocytes[2].
Mirificin (0.1 μM; 3 h) protects H9c2 rat cardiomyocytes against hypoxia/reoxygenation (H/R)-induced injury by inhibiting ALOX12 protein expression, restoring the BCL-2/BAX ratio, and reducing apoptosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Alox12-silenced H9c2 rat cardiomyocytes
-
Concentration:0.1 μM
-
Incubation Time:3 h (pretreatment prior to H/R)
-
Result:Produced no significant change in the apoptotic cell ratio compared to the H/R + siAlox12 control group.
-
Cell Line:OGD/R-injured differentiated PC12 cells
-
Concentration:5; 20; 50 μM
-
Incubation Time:24 h (pre-incubated prior to OGD/R)
-
Result:Increased cell viability to 65.8% at 5 μmol/L.
Increased cell viability to 67.4% at 20 μmol/L.
Increased cell viability to 69.5% at 50 μmol/L.
Reduced LDH leakage to 83.3% at 5 μmol/L.
Reduced LDH leakage to 84.8% at 20 μmol/L.
Reduced LDH leakage to 70.5% at 50 μmol/L.
Mirificin (12.5-25 mg/kg; i.p.; two administrations) reduces the cerebral infarction volume and improves neurological function in mice with ischemic stroke induced by middle cerebral artery occlusion (MCAO)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 6 weeks old, 18-22g, intraluminal middle cerebral artery occlusion with 2 hours of occlusion followed by reperfusion)[3]
-
Dosage:12.5 mg/kg; 25 mg/kg
-
Administration:i.p.; two time points (1 hour pre-MCAO and 1 hour post-MCAO)
-
Result:Showed a significant reduction in Longa's Neurological Severity Score and a significant decrease in cerebral infarct area at 12.5 mg/kg.
Showed significant reductions in both neurological deficit score and cerebral infarct area, with a larger reduction in infarct area than the 12.5 mg/kg group at 25 mg/kg.
Chemical Information
-
No. CAS 103654-50-8
-
Appearance Solid
-
Peso molecular 548.49
-
Fòrmula C26H28O13
-
Color White to light yellow
-
SMILES
OC1=CC=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=C1[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO[C@H](OC[C@]5(O)CO)[C@@H]5O
-
Synonyms
Puerarin apioside
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Liu H, et al. Enzyme-Site Blocking Combined with Optimization of Molecular Docking for Efficient Discovery of Potential Tyrosinase Specific Inhibitors from Puerariae lobatae Radix. Molecules. 2018 Oct 11;23(10):2612. [Content Brief]
[2]. Xing H, et al. The potential effective components from Danlou tablet attenuates acute myocardial infarction by restoring ALOX12-mediated perturbed oxylipins. Journal of ethnopharmacology. 2025 Apr 09;345:119617. [Content Brief]
[3]. Zhou Z, et al. Integrating UHPLC-MS, Network Pharmacology, and Molecular Docking techniques to explore the neuroprotective effect of Mirificin. Naunyn-Schmiedeberg's archives of pharmacology. 2026 Feb;399(4):5447-5462. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mirificin Related Classifications
HY-N2134 Related Classifications
Powered by Bioz